• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Shire PLC ADR

Shire PLC ADR

  1. All
  2. Morningstar Articles
  3. 3rd Party
  1. UPDATE: GE, Google, IBM among stocks to watch

    UPDATE: GE, Google, IBM among stocks to watch

  2. UPDATE: AbbVie woos Shire into $54 billion acquisition deal

    UPDATE: AbbVie woos Shire into $54 billion acquisition deal

  3. AbbVie woes Shire into $54 billion acquisition deal

    AbbVie woes Shire into $54 billion acquisition deal

  4. UPDATE: GE, Google, IBM among stocks to watch

    UPDATE: GE, Google, IBM among stocks to watch

  5. MARKET SNAPSHOT: U.S. Stocks: Dow Tops 17,000, Eyes Record Close

    MARKET SNAPSHOT: U.S. Stocks: Dow Tops 17,000, Eyes Record Close

  6. UPDATE: U.S. stocks: Dow tops 17,000, eyes record close

    UPDATE: U.S. stocks: Dow tops 17,000, eyes record close

  7. Shire ready to recommend AbbVie's revised $53 billion offer

    Shire ready to recommend AbbVie's revised $53 billion offer

  8. UPDATE: Shire ready to recommend AbbVie's revised $53 billion offer

    UPDATE: Shire ready to recommend AbbVie's revised $53 billion offer

  9. Lessons of the Winter Selloff

    New River Pharmaceuticals NRPH announced a buyout offer Tuesday from Shire SHPGY for $64 per share in cash, just over 3 times our fair value estimate. We'll raise our New River fair value estimate to reflect the offer price, since the transaction is already approved by both boards as well as New ...

  10. ETFs and Mutual Funds: Why not both?

    Shire Pharmaceuticals SHPGY recently announced that the FDA approved its Hunter syndrome therapy, Elaprase, for marketing. We're slightly raising our fair value estimate to account for this new addition to Shire's product portfolio. Shire received rights to Elaprase, a human enzyme replacement ...

Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.